| Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing SH Chiou, IP Winters, J Wang, S Naranjo, C Dudgeon, FB Tamburini, ... Genes & development 29 (14), 1576-1585, 2015 | 281 | 2015 |
| A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo ZN Rogers, CD McFarland, IP Winters, S Naranjo, CH Chuang, D Petrov, ... Nature methods 14 (7), 737-742, 2017 | 135 | 2017 |
| Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice ZN Rogers, CD McFarland, IP Winters, JA Seoane, JJ Brady, S Yoon, ... Nature genetics 50 (4), 483-486, 2018 | 125 | 2018 |
| Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity IP Winters, SH Chiou, NK Paulk, CD McFarland, PV Lalgudi, RK Ma, ... Nature communications 8 (1), 2053, 2017 | 107 | 2017 |
| An LKB1–SIK axis suppresses lung tumor growth and controls differentiation CW Murray, JJ Brady, MK Tsai, C Li, IP Winters, R Tang, L Andrejka, ... Cancer discovery 9 (11), 1590-1605, 2019 | 91 | 2019 |
| Zmat3 is a key splicing regulator in the p53 tumor suppression program KT Bieging-Rolett, AM Kaiser, DW Morgens, AM Boutelle, JA Seoane, ... Molecular cell 80 (3), 452-469. e9, 2020 | 74 | 2020 |
| RNA interference in marine and freshwater sponges: actin knockdown in Tethya wilhelma and Ephydatia muelleriby ingested dsRNA expressing bacteria AS Rivera, JU Hammel, KM Haen, ES Danka, B Cieniewicz, IP Winters, ... BMC biotechnology 11, 1-15, 2011 | 68 | 2011 |
| Towards quantitative and multiplexed in vivo functional cancer genomics IP Winters, CW Murray, MM Winslow Nature Reviews Genetics 19 (12), 741-755, 2018 | 52 | 2018 |
| The evolution and function of the Pax/S ix regulatory network in sponges A Rivera, I Winters, A Rued, S Ding, D Posfai, B Cieniewicz, K Cameron, ... Evolution & Development 15 (3), 186-196, 2013 | 43 | 2013 |
| Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers J Jiang, L Jiang, BJ Maldonato, Y Wang, M Holderfield, I Aronchik, ... Cancer Discovery 14 (6), 994-1017, 2024 | 35 | 2024 |
| Tumor suppressor activity of Selenbp1, a direct Nkx2-1 target, in lung adenocarcinoma DR Caswell, CH Chuang, RK Ma, IP Winters, EL Snyder, MM Winslow Molecular Cancer Research 16 (11), 1737-1749, 2018 | 35 | 2018 |
| Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma C Li, WY Lin, H Rizvi, H Cai, CD McFarland, ZN Rogers, M Yousefi, ... Cancer research 81 (17), 4570-4580, 2021 | 19 | 2021 |
| An LKB1-SIK axis suppresses lung tumor growth and controls differentiation. Cancer Discov. 2019; 9: 1590–1605. doi: 10.1158/2159-8290 CW Murray, JJ Brady, MK Tsai, C Li, IP Winters, R Tang, L Andrejka, ... CD-18-1237.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 15 | |
| Oncogenic context shapes the fitness landscape of tumor suppression LM Blair, JM Juan, L Sebastian, VB Tran, W Nie, GD Wall, M Gerceker, ... Nature Communications 14 (1), 6422, 2023 | 14 | 2023 |
| CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors F Skoulidis, HA Araujo, MT Do, Y Qian, X Sun, AG Cobo, JT Le, ... Nature, 1-10, 2024 | 1 | 2024 |
| Compositions and methods for multiplexed quantitative analysis of cell lineages MM Winslow, D Petrov, IP Winters, C McFarland, ZN Rogers US Patent 10,801,021, 2020 | 1 | 2020 |
| 21 CRISPR/Cas9-based In Vivo Models of Cancer PV Lalgudi, MM Winslow, IP Winters Genome editing and engineering: from TALENs, ZFNs and CRISPRs to molecular …, 2018 | 1 | 2018 |
| Compositions and methods for multiplexed quantitative analysis of cell lineages MM Winslow, D Petrov, IP Winters, C McFarland, ZN Rogers US Patent App. 18/433,015, 2024 | | 2024 |
| Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy IP Winters, JBM Juan, M Rosen, MM Winslow, DA Petrov, GD Wall US Patent App. 18/082,464, 2023 | | 2023 |
| Biomarkers for predicting responsiveness to shp2 inhibitor therapy IP Winters, JBM Juan, MJ Rosen, MM Winslow, DA Petrov, GD Wall US Patent App. 18/161,664, 2023 | | 2023 |